These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35103951)

  • 1. Glycemic control after switching to faster aspart in adults with type 1 diabetes.
    Fadini GP; Boscari F; Falaguasta D; Ferretto S; Maran A; Avogaro A; Bruttomesso D
    J Endocrinol Invest; 2022 Jun; 45(6):1181-1188. PubMed ID: 35103951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-World Setting: The GoBolus Study.
    Danne T; Axel Schweitzer M; Keuthage W; Kipper S; Kretzschmar Y; Simon J; Wiedenmann T; Ziegler R
    Diabetes Technol Ther; 2021 Mar; 23(3):203-212. PubMed ID: 32924568
    [No Abstract]   [Full Text] [Related]  

  • 3. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
    Akturk HK; Snell-Bergeon JK; Rewers A; Klaff LJ; Bode BW; Peters AL; Bailey TS; Garg SK
    Diabetes Technol Ther; 2018 Oct; 20(10):639-647. PubMed ID: 30207748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes.
    Baru A; Amir S; Ekelund M; Montagnoli R; Da Rocha Fernandes JD
    Postgrad Med; 2020 May; 132(4):320-327. PubMed ID: 32306819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
    Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
    Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
    Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
    Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.
    Home PD; Lindholm A; Riis A;
    Diabet Med; 2000 Nov; 17(11):762-70. PubMed ID: 11131100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): A Single-Center, Open-Label, Randomized, Crossover Trial.
    Lane WS; Weinrib SL; Lawrence MJ; Lane BC; Jarrett RT
    Endocr Pract; 2022 Feb; 28(2):165-172. PubMed ID: 34763071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial.
    Wada E; Onoue T; Kobayashi T; Handa T; Hayase A; Ito M; Furukawa M; Okuji T; Okada N; Iwama S; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Kuwatsuka Y; Ando M; Goto M; Arima H
    BMJ Open Diabetes Res Care; 2020 Jun; 8(1):. PubMed ID: 32518063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flash glucose monitoring system: impact on glycemic control and body mass index in type 1 diabetes mellitus.
    Sá JM; Lopes SC; Barbosa M; Barros IF; Santos MJ
    Arch Endocrinol Metab; 2021 Oct; 65(5):640-647. PubMed ID: 34591409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
    Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
    JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGM-based remote intervention for adults with type 1 diabetes: The FRIEND randomized clinical trial.
    Lee J; Lee MH; Park J; Kim KS; Kim SK; Cho YW; Han HW; Song YS
    Front Endocrinol (Lausanne); 2022; 13():1054697. PubMed ID: 36506077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.
    Bode BW; McGill JB; Lorber DL; Gross JL; Chang PC; Bregman DB;
    Diabetes Care; 2015 Dec; 38(12):2266-73. PubMed ID: 26180109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative contributions of fasting and postprandial glucose increments, glycemic variability, and non-glycemic factors to HbA1c in individuals with type 1 diabetes.
    Zhou Y; Zheng M; Deng H; Zheng X; Luo S; Yang D; Mai X; Xu W; Yan J; Weng J
    J Diabetes; 2023 Jun; 15(6):465-473. PubMed ID: 37143431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
    Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
    Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of "faster aspart" on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump.
    González de Buitrago Amigo J; González García A; Díaz Fernández P; Fernández Llamas M; Tejado Bravo ML; de Nicolás Jiménez JM; Ferrer Lozano M
    An Pediatr (Engl Ed); 2021 Nov; 95(5):321-329. PubMed ID: 34645579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison of Faster Insulin Aspart with Standard Insulin Aspart Using Hybrid Automated Insulin Delivery System in Active Children and Adolescents with Type 1 Diabetes: A Randomized Double-Blind Crossover Trial.
    Dovc K; Bergford S; Fröhlich-Reiterer E; Zaharieva DP; Potocnik N; Müller A; Lenarcic Z; Calhoun P; Fritsch M; Sourij H; Bratina N; Kollman C; Battelino T
    Diabetes Technol Ther; 2023 Sep; 25(9):612-621. PubMed ID: 37404205
    [No Abstract]   [Full Text] [Related]  

  • 20. Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5.
    Gorst-Rasmussen A; Sturis J; Ekelund M
    Diabetes Technol Ther; 2022 Jan; 24(1):10-17. PubMed ID: 34524005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.